No Major Heart Risk Seen in New Psoriasis Drugs, Baylor Research Institute Study

Published: Aug 24, 2011

A new, highly effective class of psoriasis drugs did not appear to raise the risk of heart problems in a review of published studies, but the analysis may not have been big enough to detect rare cases, U.S. researchers said. Abbott Laboratories pulled its U.S. and European marketing applications for one of the drugs in January, known as briakinumab [ID:nN14150334], due to concerns raised by U.S. regulators. The drug is part of a new class of treatments known as anti-IL-12/23 agents that have been shown to be highly effective at treating psoriasis, an autoimmune disease marked by well-defined patches of red raised skin.

Back to news